10-Q: Aptose Q3 2025: Tuspetinib Progress, Going Concern Doubt

Aptose Biosciences reports promising clinical data for its lead drug tuspetinib in AML, but faces significant financial challenges including a going concern warning and Nasdaq delisting.

Summary

• Net loss for the nine months ended September 30, 2025, decreased to $17.7 million from $23.8 million in the prior year.
• Cash and cash equivalents, including restricted cash, significantly decreased to $1.6 million as of September 30, 2025, from $6.7 million at December 31, 2024.
• The company has a working capital deficiency of $3.3 million as of September 30, 2025, a deterioration from a positive $5.1 million at December 31, 2024.
• Shareholders' deficit increased to $19.5 million as of September 30, 2025, from $4.5 million at December 31, 2024.
• Research and development expenses decreased by $7.7 million to $7.9 million for the nine months ended September 30, 2025, primarily due to reduced activity in the APTIVATE trial and lower manufacturing costs.
• General and administrative expenses increased by $0.9 million to $9.4 million for the nine months ended September 30, 2025, driven by higher legal and professional fees and bonuses.
• The TUSCANY Phase 1/2 clinical trial for tuspetinib in newly diagnosed AML patients showed promising safety and antileukemic activity, with 90% CR/CRh responses and 78% MRD-negativity in responding patients.
• Dose escalation for tuspetinib in the TUSCANY trial progressed to 160 mg, with 4 patients dosed as of October 30, 2025.
• Development of luxeptinib has been paused due to funding constraints and prioritization of tuspetinib.
• The company was delisted from Nasdaq on April 2, 2025, for failing to meet the minimum stockholders' equity requirement and is now trading on the OTCQB Market.
• A material weakness in internal control over financial reporting related to accounting for complex financial instruments (warrants) was identified.
• The company relies heavily on advances from Hanmi Pharmaceutical Co. Ltd. for operations, having utilized $8.5 million from one facility and received $4.2 million from an amended facility as of the filing date.

Sentiment

Score: 3

Explanation: While clinical data for tuspetinib is positive, the severe financial condition, including a going concern warning, Nasdaq delisting, and reliance on uncommitted related-party financing, presents substantial risks to the company's viability and future operations.

Positives

• Tuspetinib's TUSCANY Phase 1/2 trial shows promising clinical safety and antileukemic activity in newly diagnosed AML patients.
• The TUS+VEN+AZA triplet achieved CR/CRh responses in 9/10 (90%) patients, exceeding the 66% rate expected from VEN+AZA alone at higher dose levels (80mg and 120mg).
• MRD-negativity was noted in 7/9 (78%) responding patients by central flow cytometry.
• Tuspetinib demonstrated a favorable safety profile with no dose-limiting toxicities, no treatment-related deaths, no QTc prolongation, no prolonged myelosuppression after remission, and no CPK elevations.
• Responses were achieved across diverse mutational subtypes, including unmutated FLT3, FLT3-ITD, NPM1c, biallelic TP53 with complex karyotype, RAS, and myelodysplasia related mutations.
• The FDA granted orphan drug designation to tuspetinib for treating AML in October 2018, providing potential marketing exclusivity and other benefits.
• A Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for tuspetinib's clinical development in myeloMATCH trials.
• Preclinical studies suggest tuspetinib targets venetoclax (VEN) resistance mechanisms and can prevent the emergence of resistance to both agents when combined with VEN.
• Net loss decreased by $6.1 million for the nine months ended September 30, 2025, compared to the same period in 2024.
• Cash used in operating activities decreased by $11.768 million for the nine months ended September 30, 2025, compared to the same period in 2024.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern within one year.
• Cash and cash equivalents, including restricted cash, decreased significantly from $6.7 million at December 31, 2024, to $1.6 million at September 30, 2025.
• The company has a working capital deficiency of $3.3 million as of September 30, 2025, a significant deterioration from a positive $5.1 million at December 31, 2024.
• Shareholders' deficit increased to $19.5 million as of September 30, 2025, from $4.5 million at December 31, 2024.
• Delisted from Nasdaq on April 2, 2025, due to failure to meet the minimum stockholders' equity requirement of $2.5 million.
• Development of luxeptinib has been paused due to current funding constraints and prioritization of tuspetinib.
• Discontinued further clinical development of APTO-253.
• Identified a material weakness in internal control over financial reporting related to accounting for complex financial instruments (warrants).
• The Hanmi facility agreements are uncommitted, and Hanmi may cancel availability at any time without notice, acting solely at its discretion.
• The company relies heavily on advances from Hanmi for operations and does not have sufficient cash to fund operations independently.
• Difficulty for micro-cap market capitalization companies to raise significant capital.

Risks

• Ability to continue as a going concern.
• Need to raise substantial additional capital in the near future and ability to raise such funds when needed and on acceptable terms.
• If a financing is completed, it may not be large enough to fully fund operations.
• Suppliers or clinical sites may implement work stoppages, change contract terms, or terminate contracts for key programs.
• Conversations with partners to renegotiate existing product license agreements may not be successful.
• Lack of product revenues and net losses, and a history of operating losses.
• Ability to meet continued listing requirements of the TSX and relist on Nasdaq.
• Early stage of development, with inherent risks and uncertainties in developing new drug candidates, demonstrating safety/efficacy, and obtaining regulatory approval.
• Further equity financing may substantially dilute existing shareholders.
• Clinical studies and regulatory approvals are subject to delays and may not be completed or granted on expected timetables, increasing costs and harming the business.
• Reliance on external contract research/manufacturing organizations, with risks of quality, cost, or delivery issues.
• Clinical studies are long, expensive, may have uncertain outcomes, and product candidates may not be approved by the FDA or other agencies.
• Ability to comply with applicable governmental regulations and standards.
• Inability to achieve projected development goals in announced time frames.
• Difficulties in enrolling patients for clinical trials may lead to delays or cancellations.
• Ability to maintain an adequate supply of clinical drug product.
• Impact of government spending cuts.
• Reliance on third parties to conduct and monitor preclinical studies.
• Ability to attract and retain key personnel.
• Misconduct or improper activities by employees.
• Exposure to exchange rate risk.
• Ability to commercialize business attributed to negative results from clinical trials.
• Marketplace may not accept products due to intense competition and technological change.
• Ability to obtain and maintain patent protection.
• Ability to afford substantial costs incurred with defending intellectual property.
• Ability to protect intellectual property rights and not infringe on others' rights.
• Business is subject to potential product liability and other claims.
• Potential exposure to legal actions and need to take action against other entities.
• Commercialization limitations imposed by third-party intellectual property rights.
• Ability to maintain adequate insurance at acceptable costs.
• Ability to find and enter into agreements with potential partners.
• Extensive government regulation.
• Data security incidents and privacy breaches.
• Share price has been and is likely to continue to be volatile.
• Future sales of common shares by the company or existing shareholders could cause share price to drop.
• Changing global market and financial conditions.
• Changes in an active trading market in common shares.
• Difficulties for non-Canadian investors to obtain and enforce judgments against the company due to Canadian incorporation.
• Potential adverse U.S. federal tax consequences for U.S. shareholders because the company is a passive foreign investment company.
• Smaller reporting company status.
• Failures to maintain an effective system of internal controls may result in material misstatements, failure to meet reporting obligations, or failure to prevent fraud.
• Broad discretion in how proceeds from common share sales are used.
• Ability to expand business through acquisition of companies or businesses.
• Risk of imminent bankruptcy.
• Need to obtain substantial funding immediately in order to continue operations and exploration of strategic alternatives.
• Suppliers may face challenges due to increased tariffs, geopolitical tensions, regulatory changes, and dependencies in the global supply chain, leading to higher costs, delays, or interruptions.
• One contract research organization represented 35% of accounts payable as of September 30, 2025, with $1.4 million owed as of the filing date after a $0.5 million payment.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future until regulatory approval and commercialization of products, or until royalty or milestone revenue from such products exceeds expenses. Research and development expenses are expected to be lower in 2025 than in 2024, but will increase as tuspetinib advances into more extensive clinical trials unless partnered. General and administrative expenses are expected to increase slightly due to ongoing personnel, legal, and insurance costs. The company plans to raise additional funds through debt or other financing activities, but there is no assurance of obtaining additional liquidity when needed or under acceptable terms, if at all.

Management Comments

• "Management recognizes that to meet the capital requirements and continue to operate, additional financing will be necessary."
• "Management continues considering options for raising capital including debt, through collaborations or reorganization to reduce operational expenses."
• "However, given the decrease in the share price, the Company's delisting from Nasdaq... as well as the difficulty for micro-cap market capitalization companies to raise significant capital, there can be no assurance that the Company will be able to obtain additional liquidity when needed or under acceptable terms, if at all."
• "If debt or equity financing is unable to be secured or contemplated, and trade sales fail to materialize, we may need to resolve to other means of protecting our assets in the best interests of our shareholders, including foreclosure or forced liquidation and/or seeking creditors protection."
• "These beliefs regarding potential patient treatment and commercial opportunities are based on managements current assumptions and estimates, which are subject to change, and there can be no assurance that tuspetinib will ever be approved or successfully commercialized, or that, if approved and commercialized, it will ever generate significant revenues."
• "We are not exploring alternative development paths or collaborations for LUX. Given current funding and our prioritization of tuspetinib, we have paused funding the development of luxeptinib."

Industry Context

The company operates in the highly competitive and technologically dynamic biotechnology and pharmaceutical industry, specifically focusing on hematologic oncology. The development of triplet therapies for AML, like Aptose's TUS+VEN+HMA, aims to address the significant unmet need for improved frontline treatments, especially for older patients who often fail standard therapies. The focus on mutation-agnostic approaches and targeting venetoclax resistance mechanisms positions tuspetinib to potentially differentiate itself in a crowded market. The collaboration with the NCI through myeloMATCH trials indicates alignment with broader industry efforts to accelerate precision medicine in AML and MDS. The pausing of luxeptinib development reflects a common industry practice of prioritizing lead assets in resource-constrained environments.

Comparison to Industry Standards

• The TUS+VEN+AZA triplet achieved CR/CRh responses in 6/6 (100%) patients treated at higher dose levels (80 mg and 120 mg TUS), exceeding the 66% rate expected from VEN+AZA alone, suggesting a potentially superior efficacy profile compared to the current standard of care doublet.
• Tuspetinib's favorable safety profile, with no drug-related QTc prolongations, significant liver/kidney toxicities, muscle damage, differentiation syndrome, or myelosuppression with continuous dosing, differentiates it from other kinase inhibitors that often cause such toxicities.
• Preclinical studies showing tuspetinib targets VEN resistance mechanisms and retains nanomolar potency against AML cells engineered for resistance to VEN suggest a potential advantage in overcoming a common challenge in AML treatment, which is the emergence of resistance to venetoclax. This positions tuspetinib as a potential solution for a rapidly growing population of patients who fail prior venetoclax therapy, a segment where median overall survival is very low (e.g., 7.2 months for R/R AML patients receiving chemotherapy after failing HMA-VEN, and 4.3 months for older patients).

Corporate Governance

Related Party Transactions

• Hanmi Pharmaceutical Co. Ltd.: Tuspetinib Licensing Agreement (November 4, 2021), Supply Agreement (2022), Hanmi Loan Agreement ($10.0 million, August 27, 2024) with $1.5 million converted to 409,063 Common Shares on March 18, 2025. Hanmi Facility Agreement (up to $8.5 million, June 18, 2025), fully utilized. Amended Facility Agreement (up to $11.9 million, September 22, 2025), with $4.2 million received as of the filing date. Hanmi holds a first ranking general security interest over company assets, including Tuspetinib inventory and licensing data. Hanmi holds 508,710 Common Shares and 77,972 warrants.
• CEO Short-Term Advance: $100,000 interest-free advance from CEO on June 17, 2025, repaid on June 26, 2025.

Stakeholder Impact

• Shareholders: Significant dilution risk from future equity financings; potential for total loss of investment if the company cannot continue as a going concern; share price volatility; delisting from Nasdaq to OTCQB may reduce liquidity and investor interest.
• Employees: Potential for job insecurity or reorganization if the company faces financial distress or needs to reduce operational expenses.
• Customers (future patients): Potential for delays or discontinuation of promising drug candidates (like tuspetinib) if funding is not secured, impacting access to new treatments for AML.
• Suppliers/Creditors: Risk of non-payment or delayed payments, as evidenced by one CRO representing 35% of accounts payable. Hanmi, as a related-party creditor, has a security interest over key assets.

Next Steps

• Select two dose levels for expansion in the TUSCANY study and dose up to 10 patients total on each.
• Continue delivering additional clinical data (CR and MRD negativity rates, safety, and survival) from the TUSCANY study over the next 6 to 12 months.
• Advance optimal doses from the TUSCANY study into Phase 2/3 clinical trials.
• Implement remediation actions for the material weakness in internal control over financial reporting, including identifying specific clauses for warrant liability classification, engaging a specialized firm, and providing additional guidance and training to employees.
• Raise additional funds through debt or other financing activities to fund business operations.
• Explore collaborations or reorganization to reduce operational expenses.
• Negotiate a co-development collaboration agreement for tuspetinib with Hanmi, which would convert the Hanmi Loan Agreement principal and interest into prepayment of future milestone obligations.

Key Dates

Recommendation

Despite promising early clinical data for tuspetinib, the company faces severe financial distress, including a "substantial doubt" about its ability to continue as a going concern, a significant cash deficit, negative working capital, and delisting from Nasdaq. Its reliance on uncommitted related-party financing from Hanmi, which can be cancelled at any time, highlights extreme liquidity risk. The identified material weakness in internal controls further compounds these concerns. The potential for significant dilution from future capital raises or even foreclosure/liquidation makes the stock a high-risk investment with a strong likelihood of further value erosion.

Keywords

Aptose Biosciences, Tuspetinib, AML, Acute Myeloid Leukemia, Oncology, Hematology, Clinical Trial, TUSCANY Study, Venetoclax, Azacitidine, Triplet Therapy, Orphan Drug, Nasdaq Delisting, Going Concern, Biotechnology, Pharmaceuticals, Drug Development, Luxeptinib, Financial Reporting, SEC Filing, Capital Raise, Hanmi Pharmaceutical, MRD-negativity, CR/CRh, FLT3, TP53, RAS mutation, Myeloid Kinase Inhibitor